29 February 2024 in Journal of Clinical Investigation
RAD54 and BLM helicase play pivotal roles during homologous recombination repair (HRR) to ensure genome maintenance. BLM amino acids (aa 181–212) interact with RAD54 and enhance its chromatin remodeling activity. Functionally, this interaction heightens HRR, leading to a decrease in residual DNA damage in colon cancer cells. This contributes to chemoresistance in colon cancer cells against cisplatin, camptothecin, and oxaliplatin, eventually promoting tumorigenesis in preclinical colon cancer mouse models. ChIP-Seq analysis and validation revealed increased BLM and RAD54 corecruitment on the MRP2 promoter in camptothecin-resistant colon cancer cells, leading to BLM-dependent enhancement of RAD54-mediated chromatin remodeling. We screened the Prestwick small-molecule library, with the intent to revert camptothecin- and oxaliplatin-induced chemoresistance by disrupting the RAD54-BLM interaction. Three FDA/European Medicines Agency–approved candidates were identified that could disrupt this interaction. These drugs bound to RAD54, altered its conformation, and abrogated RAD54-BLM–dependent chromatin remodeling on G5E4 and MRP2 arrays. Notably, the small molecules also reduced HRR efficiency in resistant lines, diminished anchorage-independent growth, and hampered the proliferation of tumors generated using camptothecin- and oxaliplatin-resistant colon cancer cells in both xenograft and syngeneic mouse models in BLM-dependent manner. Therefore, the 3 identified small molecules can serve as possible viable candidates for adjunct therapy in colon cancer treatment.
4 March 2025 in The EMBO Journal
The DREAM repressor complex regulates genes involved in the cell cycle and DNA repair, vital for maintaining genome stability. Although it mediates p53-driven repression through the canonical p53-p21-Rb axis, the potential for p53 to directly regulate DREAM targets independently of its transcriptional activity has not been explored. Here, we demonstrate that in asynchronously growing cells, p53 loss leads to greater de-repression of DREAM targets compared to p21 loss alone. Both wild-type and transactivation-deficient p53 mutants are capable of repressing DREAM targets, suggesting a transactivation-independent “non-canonical” repression mechanism. These p53 variants bind p130/p107, irrespective of their phosphorylation status, while cancer-associated p53 mutants disrupt DREAM complex function by sequestering E2F4. Re-ChIP analysis shows co-recruitment of p53 and E2F4 to known and newly identified DREAM target promoters, indicating direct repression of these targets by p53. These findings reveal a novel, transactivation-independent mechanism of p53-mediated repression, expanding our understanding of p53’s tumor-suppressive functions and suggesting DREAM complex targeting as potential future avenues in cancer therapy.
20 May 2026 in Cell Death & Disease
Loss of BLM helicase leads to Bloom Syndrome, characterized by genomic instability, cancer predisposition and immunodeficiency. We now show that BLM is essential for the proliferation of cycling B cells and sustains B-cell development by maintaining NF-κB signalling. Hence, in the absence of BLM, the NF-κB pathway is impaired as visualized by the lack of the nuclear translocation of RelA. This action of BLM is due to its binding to the MALT1 promoter (a key positive regulator of NF-κB signalling) and activating its transcription. Reintroduction of MALT1 and constitutively active IKKβ rescues B-cell development in BLM-deficient bone marrow and spleen cells of BLM knockout mice. This indicates that downregulation of MALT1 in BLM-deficient cells is the primary cause of deregulated NF-κB signalling and impaired B-cell development. Interestingly, the pro-proliferative role of BLM can be exploited in the treatment of B-cell malignancies. Here, we demonstrate that depletion of BLM (phenocopied by the inhibition of MALT1) suppresses the progression of lymphoma and leukaemia by inhibiting MALT1-dependent NF-κB signalling and sensitizing malignant B cells to chemotherapy. Together, our findings establish the BLM-MALT1-NF-κB axis as a critical regulator of B-cell development and demonstrate its therapeutic potential in B-cell malignancies. Hence, both upregulation and downregulation of BLM contribute to oncogenesis, underscoring the need to maintain its expression within a tightly controlled threshold.